Fig. 2

Stable overexpression of SOX17 sensitizes ESCC cell line to cisplatin, radiation and chemoradiation treatments. a-c Cell viability was measured by MTT assay in KYSE510-SOX17 stable cells treated with various doses of cisplatin (a), radiation (b), or CCRT (concurrent cisplatin and radiation treatment) (c) for 72 h. KYSE510-SOX17 stable cells were more sensitive to treatments described above than KYSE510-EV (empty vector) cells. Western blot analysis confirmed that SOX17 protein was stably expressed in KYSE510-SOX17 cell, but not in KYSE510-EV cell (upper right panel in a). d, e Clonogenic survival was measured at day 6 after replating the KYSE510-SOX17 or KYSE510-EV cells treated with different doses of cisplatin (d) or radiation (e) for 72 h. The foci formation ability of KYSE510-SOX17 stable cells were reduced compared to KYSE510-EV cells. Data are mean ± S.D. from three independent experiments. P-values were determined by two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001